Argitalpenak (83) Jose Ignacio Rodríguez Barbosa argitalpenak

2023

  1. Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression

    Frontiers in Immunology, Vol. 14

2022

  1. Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib

    Scientific Reports, Vol. 12, Núm. 1

  2. Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance

    Frontiers in Immunology, Vol. 13

  3. The Role of the Inhibitory Ligand HVEM and Its Receptors CD160 and BTLA in the Regulation of Anti-retroviral T Cell Responses

    Frontiers in Virology, Vol. 2

  4. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection

    Translational Research, Vol. 239, pp. 103-123

2021

  1. Calidad de vida del receptor de un órgano sólido en Castilla y León

    Revista ROL de enfermería, Vol. 44, Núm. 5, pp. 12-20

  2. Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases

    Frontiers in Immunology

2020

  1. Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model

    Cancer Immunology, Immunotherapy, Vol. 69, Núm. 6, pp. 1001-1014

  2. The role of TNFR2 and DR3 in the in vivo expansion of tregs in t cell depleting transplantation regimens

    International Journal of Molecular Sciences, Vol. 21, Núm. 9

2019

  1. CD160 serves as a negative regulator of NKT cells in acute hepatic injury

    Nature Communications, Vol. 10, Núm. 1

  2. Correction to: T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway (Cellular and Molecular Immunology, (2017), 14, 6, (497-510), 10.1038/cmi.2015.101)

    Cellular and Molecular Immunology

  3. HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT

    Cellular and Molecular Immunology, Vol. 16, Núm. 7, pp. 679-682

2018

  1. Descripción de la calidad de vida de los pacientes con trasplante renal del Principado de Asturias

    Tiempos de enfermería y salud = Nursing and health times, Núm. 4, pp. 20-24

  2. Downregulation of BTLA on NKT cells promotes tumor immune control in a mouse model of mammary Carcinoma

    International Journal of Molecular Sciences, Vol. 19, Núm. 3

  3. Therapeutic implications of NK cell regulation of allogeneic CD8 T cell-mediated immune responses stimulated through the direct pathway of antigen presentation in transplantation

    mAbs, Vol. 10, Núm. 7, pp. 1030-1044

2017

  1. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier

    Translational Research, Vol. 181, pp. 83-95.e3

  2. T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway

    Cellular and Molecular Immunology, Vol. 14, Núm. 6, pp. 497-510

2016

  1. Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells

    mAbs, Vol. 8, Núm. 3, pp. 478-490

  2. Porcine islet-specific tolerance induced by the combination of anti-LFA-1 and anti-CD154 mabs is dependent on PD-1

    Cell Transplantation, Vol. 25, Núm. 2, pp. 327-342

  3. The European antibody network’s practical guide to finding and validating suitable antibodies for research

    mAbs, Vol. 8, Núm. 1, pp. 27-36